Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Open accessThe DOI matches its Crossref record; 295 of the 295 references it cites were found in a registry or an index.
Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is the third leading cause of tumor-related mortality worldwide. In recent years, the emergency of immune checkpoint inhibitor (ICI) has revolutionized the management of HCC. Especially, the combination of atezolizumab (anti-PD1) and bevacizumab (anti-VEGF) has been approved by the FDA as the first-line treatment for advanced HCC. Despite great breakthrough in systemic therapy, HCC continues to portend a poor prognosis owing to drug resistance and frequent recurrence. The tumor microenvironment (TME) of HCC is a complex and structured mixture characterized by abnormal angiogenesis, chronic inflammation, and dysregulated extracellular matrix (ECM) remodeling, collectively contributing to the immunosuppressive milieu that in turn prompts HCC proliferation, invasion, and metastasis. The tumor microenvironment coexists and interacts with various immune cells to maintain the development of HCC. It is widely accepted that a dysfunctional tumor-immune ecosystem can lead to the failure of immune surveillance. The immunosuppressive TME is an external cause for immune evasion in HCC consisting of 1) immunosuppressive cells; 2) co-inhibitory signals; 3) soluble cytokines and signaling cascades; 4) metabolically hostile tumor microenvironment; 5) the gut microbiota that affects the immune microenvironment. Importantly, the effectiveness of immunotherapy largely depends on the tumor immune microenvironment (TIME). Also, the gut microbiota and metabolism profoundly affect the immune microenvironment. Understanding how TME affects HCC development and progression will contribute to better preventing HCC-specific immune evasion and overcoming resistance to already developed therapies. In this review, we mainly introduce immune evasion of HCC underlying the role of immune microenvironment, describe the dynamic interaction of immune microenvironment with dysfunctional metabolism and the gut microbiome, and propose therapeutic strategies to manipulate the TME in favor of more effective immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–295 of 295
Li, F., Zhao, Y., Wei, L., Li, S., & Liu, J. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1450116 · Cited by 138
Teng, K.-Y., Han, J., Zhang, X., Hsu, S.-H., He, S., Wani, N. A., Barajas, J. M., Snyder, L. A., Frankel, W. L., Caligiuri, M. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0124 · Cited by 134
Chen, M., Yan, B., Lu, W., Chen, M., Yu, S., Yang, P., & Ann‐Lii, C. (2013) · International Journal of Cancer · doi:10.1002/ijc.28362 · Cited by 131
Courau, T., Nehar-Belaid, D., Florez, L., Levacher, B., Vazquez, T., Brimaud, F., Bellier, B., & Klatzmann, D. (2016) · JCI Insight · doi:10.1172/jci.insight.85974 · Cited by 131
Krämer, B., Körner, C., Kebschull, M., Glässner, A., Eisenhardt, M., Nischalke, H.-D., Alexander, M., Sauerbruch, T., Spengler, U., & Nattermann, J. (2012) · Hepatology · doi:10.1002/hep.25804 · Cited by 130
Signaling pathways bridging microbial-triggered inflammation and cancer
Kipanyula, M. J., Etet, P. F. S., Vecchio, L., Farahna, M., Nukenine, E. N., & Kamdje, A. H. N. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.10.014 · Cited by 128
Yi, Y., He, H.-W., Wang, J., Cai, X., Li, Y.-W., Zhou, J., Cheng, Y., Jin, J., Fan, J., & Qiu, S. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.015 · Cited by 126
Association Analysis of IL-17A and IL-17F Polymorphisms in Chinese Han Women with Breast Cancer
Wang, L., Jiang, Y., Zhang, Y., Wang, Y., Huang, S., Wang, Z., Tian, B., Yang, Y., Jiang, W., & Pang, D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034400 · Cited by 126
Self-citationBrown, Z. J., Yu, S. J., Heinrich, B., Ma, C., Fu, Q., Sandhu, M., Agdashian, D., Zhang, Q., Korangy, F., & Greten, T. F. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2190-4 · Cited by 122
The influence of microenvironment on tumor immunotherapy
Zhang, J., Shi, Z., Xu, X., Yu, Z., & Mi, J. (2019) · FEBS Journal · doi:10.1111/febs.15028 · Cited by 118
Pomatto-Watson, L. C. D., Bodogai, M., Bosompra, O., Kato, J., Wong, S., Carpenter, M., Duregon, E., Chowdhury, D., Krishna, P., Ng, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26431-4 · Cited by 118
The application of probiotics in cancer
de LeBlanc, A. D. M., Matar, C., & Perdigón, G. (2007) · British Journal Of Nutrition · doi:10.1017/s0007114507839602 · Cited by 116
Portal and systemic bacteraemia and endotoxaemia in liver disease.
Triger, D. R., Boyer, T. D., & Levin, J. (1978) · Gut · doi:10.1136/gut.19.10.935 · Cited by 114
Maini, M. K., & Pallett, L. J. (2018) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(18)30007-4 · Cited by 113
Kumar, M., Verma, V., Nagpal, R., Kumar, A., Gautam, S. K., Behare, P. V., Grover, C. R., & Aggarwal, P. (2011) · Gene · doi:10.1016/j.gene.2011.09.003 · Cited by 111
Liu, W., Jing, Y., Yu, G., Han, Z., Yu, D., Fan, Q., Ye, F., Li, R., Gao, L., Zhao, Q., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.019 · Cited by 111
Very‐low‐carbohydrate diet enhances human T‐cell immunity through immunometabolic reprogramming
Hirschberger, S., Strauß, G., Effinger, D., Marstaller, X., Ferstl, A., Müller, M. B., Wu, T., Hübner, M., Rahmel, T., Mascolo, H., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114323 · Cited by 108
Notch-mediated lactate metabolism regulates MDSC development through the Hes1/MCT2/c-Jun axis
Zhao, J., Ye, Y., Gao, C.-C., Wang, L., Ren, K., Jiang, R., Hu, S., Liang, S.-Q., Bai, J., Liang, J.-L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110451 · Cited by 108
M. de-Brito, N., Duncan-Moretti, J., C. da-Costa, H., Saldanha-Gama, R., Paula-Neto, H. A., G. Dorighello, G., L. Simões, R., & Barja-Fidalgo, C. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118604 · Cited by 107
Gut flora and bacterial translocation in chronic liver disease
Almeida, J. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i10.1493 · Cited by 106
Huang, Y. L., Wang, F., Wang, T., Wang, Y., Zhu, Z., Gao, Y., & Zhi, D. (2012) · Digestion · doi:10.1159/000342801 · Cited by 106
Toll-Like Receptor 2 at the Crossroad between Cancer Cells, the Immune System, and the Microbiota
Lorenzo, A. D., Bolli, E., Tarone, L., Cavallo, F., & Conti, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249418 · Cited by 105
Iwata, T., Kondo, Y., Kimura, O. S., Morosawa, T., Fujisaka, Y., Umetsu, T., Kogure, T., Inoue, J., Nakagome, Y., & Shimosegawa, T. (2016) · Scientific Reports · doi:10.1038/srep39296 · Cited by 103
Soundararajan, R., Fradette, J., Konen, J., Moulder, S., Zhang, X., Gibbons, D., Varadarajan, N., Wistuba, I., Tripathy, D., Bernatchez, C., et al. (2019) · Cancers · doi:10.3390/cancers11050714 · Cited by 103
Cross-presentation of antigen by diverse subsets of murine liver cells
Ebrahimkhani, M. R., Mohar, I., & Crispe, I. N. (2011) · Hepatology · doi:10.1002/hep.24508 · Cited by 102 · cited 1×
“Kupffer cells are liver-resident macrophages that act as antigenpresenting cells (APC) to form the first line of defense against pathogens (78, 79).”
BackgroundIDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
Amobi, A. E., Muthuswamy, R., Battaglia, S., Yu, H., Liu, T., Wang, J., Putluri, V., Singh, P. K., Qian, F., Huang, R.-Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.678999 · Cited by 102
Wang, L., Zhu, R., Huang, Z., Li, H., & Zhu, H. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2745-3 · Cited by 100
Okumoto, K., Hattori, E., Tamura, K., Kiso, S., Watanabe, H., Saito, K., Saito, T., Togashi, H., & Kawata, S. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00882.x · Cited by 99
Lin, T.-H., Shao, Y.-Y., Chan, S.-Y., Huang, C.-Y., Hsu, C.-H., & Cheng, A.-L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1954 · Cited by 99
Dong, X., Liu, T., Zhi, X., Zou, J., Zhong, J., Li, T., Mo, X.-L., Zhou, W., Guo, W., Liu, X., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2725 · Cited by 99
Self-citationLi, Z., Li, N., Li, F., Zhou, Z., Sang, J., Chen, Y., Han, Q., Lv, Y., & Liu, Z. (2016) · Medicine · doi:10.1097/md.0000000000005749 · Cited by 98
The Resistance Mechanisms of Lung Cancer Immunotherapy
Wang, F., Wang, S., & Zhou, Q. H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568059 · Cited by 98
Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint
Schmidt, N. M., Wing, P. A. C., Diniz, M. O., Pallett, L. J., Swadling, L., Harris, J. M., Burton, A. R., Jeffery-Smith, A., Zakeri, N., Amin, O. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22967-7 · Cited by 98
Cutting Edge: Hypoxia-Inducible Factor 1 Negatively Regulates Th1 Function
Shehade, H., Acolty, V., Moser, M., & Oldenhove, G. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402552 · Cited by 96
Microbiota—myeloid cell crosstalk beyond the gut
Gorjifard, S., & Goldszmid, R. S. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ri0516-222r · Cited by 96
Concise Review: Contribution of Cancer Stem Cells to Neovascularization
Ping, Y., & Bian, X. (2011) · Stem Cells · doi:10.1002/stem.650 · Cited by 94
Missiaen, R., Mazzone, M., & Bergers, G. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.002 · Cited by 94
Sun, H., Yang, W., Tian, Y., Zeng, X., Zhou, J., Mok, M. T. S., Tang, W., Feng, Y., Xu, L., Chan, A. W. H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07402-8 · Cited by 93
Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade
Zha, H., Han, X., Zhu, Y. J., Yang, F., Li, Y., Li, Q., Guo, B., & Zhu, B. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1349587 · Cited by 92
Defective HLA class I antigen processing machinery in cancer
Cai, L., Michelakos, T., Yamada, T., Fan, S., Wang, X., Schwab, J. H., Ferrone, C. R., & Ferrone, S. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2131-2 · Cited by 90
Maisonneuve, C., Tsang, D. K. L., Foerster, E. G., Robert, L. M., Mukherjee, T., Prescott, D., Tattoli, I., Lemire, P., Winer, D. A., Winer, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108677 · Cited by 90
Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma
Dai, X., Guo, Y., Hu, Y., Bao, X., Zhu, X., Fu, Q., Zhang, H., Tong, Z., Liu, L., Zheng, Y., et al. (2021) · Theranostics · doi:10.7150/thno.54648 · Cited by 89
CD47: the next checkpoint target for cancer immunotherapy
Feng, R., Hai, Z., Xu, J., & Shen, C. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103014 · Cited by 88
Xu, M., Zhao, Z., Song, J., Lan, X., Lu, S., Chen, M., Wang, Z., Chen, W., Fan, X., Wu, F., et al. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.01.008 · Cited by 85
Self-citationVancomycin prevents fermentable fiber-induced liver cancer in mice with dysbiotic gut microbiota
Singh, V., Yeoh, B. S., Abokor, A. A., Golonka, R. M., Tian, Y., Patterson, A. D., Joe, B., Heikenwälder, M. F., & Vijay–Kumar, M. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1743492 · Cited by 85
Cadoux, M., Caruso, S., Pham, S., Gougèlet, A., Pophillat, C., Riou, R., Loesch, R., Colnot, S., Nguyễn, C. T., Caldéraro, J., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.017 · Cited by 83
Zhang, C., Wang, N., Tan, H., Guo, W., Chen, F., Zhong, Z., Man, K., Tsao, S. W., Lao, L., & Feng, Y. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15046 · Cited by 82
Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?
Finlay, B. B., Goldszmid, R., Honda, K., Trinchieri, G., Wargo, J., & Zitvogel, L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0374-6 · Cited by 81
Gut microbiota: A new piece in understanding hepatocarcinogenesis
Zhou, A., Tang, L., Zeng, S., Lei, Y., Yang, S., & Tang, B. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.002 · Cited by 80
Li, L., Yan, J., Xu, J., Liu, C.-Q., Zhen, Z. J., Chen, H., Ji, Y., Wu, Z.-P., Hu, J. Y., Zheng, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110064 · Cited by 79
Rojo, D., Hevia, A., Bargiela, R., López, P., Cuervo, A., González, S., Suárez, A., Sánchez, B., Martínez-Martínez, M., Milani, C., et al. (2015) · Scientific Reports · doi:10.1038/srep08310 · Cited by 79
Cai, H., Zhu, X., Ao, J., Ye, B., Zhang, Y.-Y., Chai, Z., Wang, C.-H., Shi, W.-K., Cao, M.-Q., Li, X., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1333213 · Cited by 79
Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti‐tumor immunity
Sipe, L. M., Chaib, M., Pingili, A. K., Pierre, J. F., & Makowski, L. (2020) · Immunological Reviews · doi:10.1111/imr.12856 · Cited by 78
Cai, X., Ni, X., Yi, Y., He, H.-W., Wang, J., Fu, Y., Sun, J., Zhou, J., Cheng, Y., Jin, J., et al. (2016) · Medicine · doi:10.1097/md.0000000000004989 · Cited by 76
Fu, Y., Yi, Y., Cai, X., Sun, J., Ni, X., He, H.-W., Wang, J., Lu, Z., Huang, J., Cao, Y., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.47 · Cited by 73
Shah, A., Shanahan, E., Macdonald, G., Fletcher, L., Ghasemi, P., Morrison, M., Jones, M., & Holtmann, G. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1608832 · Cited by 73
Cao, M., Cabrera, R., Xu, Y., Firpi, R. J., Zhu, H., Liu, C., & Nelson, D. R. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700540 · Cited by 69
Eiró, N., Altadill, A., Salcedo, L. M. J., Rodríguez, M., González, L. O., Atienza, S., Bermúdez, S., Fernández‐García, B., Fresno-Forcelledo, M. F., Rodrigo, L., et al. (2013) · Hepatology Research · doi:10.1111/hepr.12180 · Cited by 69
Pedroza‐González, A., Zhou, G., Singh, S. P., Boor, P. P. C., Pan, Q., Grünhagen, D. J., de Jonge, J., Tran, T. K., Verhoef, C. K., IJzermans, J. N. M., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1051297 · Cited by 69
Zhong, M., Zhong, C., Cui, W., Wang, G., Zheng, G., Li, L., Zhang, J., Ren, R., Gao, H., Wang, T., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5670-9 · Cited by 69
Yang, J. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i23.2938 · Cited by 65
Grote, V. A., Kaaks, R., Nieters, A., Tjønneland, A., Halkjær, J., Overvad, K., Skjelbo Nielsen, M. R., Boutron-Ruault, M. C., Clavel-Chapelon, F., Racine, A., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.172 · Cited by 65
The Helicobacter pylori HopQ outermembrane protein inhibits immune cell activities
Gur, C., Maalouf, N., Gerhard, M., Singer, B. B., Emgård, J., Temper, V., Neuman, T., Mandelboim, O., & Bachrach, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1553487 · Cited by 65
The microbiome and cytosolic innate immune receptors
Liwinski, T., Zheng, D., & Elinav, E. (2020) · Immunological Reviews · doi:10.1111/imr.12901 · Cited by 65
Human CCR4+CCR6+Th17 Cells Suppress Autologous CD8+ T Cell Responses
Zhao, F., Hoechst, B., Gamrekelashvili, J., Ormandy, L. A., Voigtländer, T., Wedemeyer, H. H., Ylaya, K., Wang, X. W., Hewitt, S. M., Manns, M. P., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102918 · Cited by 64
LPS promotes epithelial–mesenchymal transition and activation of TLR4/JNK signaling
Li, H., Li, Y., Liu, D., & Liu, J. (2014) · Tumor Biology · doi:10.1007/s13277-014-2347-5 · Cited by 64
Audrito, V., Managò, A., Gaudino, F., Sorci, L., Messana, V. G., Raffaelli, N., & Deaglio, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01720 · Cited by 64
Wu, C.-J., Tsai, Y.-T., Lee, I., Wu, P., Lu, L., Tsao, W.-S., Huang, Y.-J., Chang, C.-C., Ka, S., & Tao, M. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1477459 · Cited by 61
Cariani, E., Pilli, M., Zerbini, A., Rota, C., Olivani, A., Zanelli, P., Zanetti, A., Trenti, T., Ferrari, C. I., & Missale, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0986 · Cited by 56
Cariani, E., Pilli, M., Barili, V., Porro, E., Biasini, E., Olivani, A., Valle, R. D., Trenti, T., Ferrari, C. I., & Missale, G. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1154249 · Cited by 54
Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model
Li, G., Liu, D., Cooper, T. K., Kimchi, E. T., Qi, X., Avella, D. M., Li, N., Yang, Q. X., KESTER, M. A., Rountree, C. B., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.044 · Cited by 53
Sharma, S., Khosla, R., David, P., Rastogi, A., Vyas, A. K., Singh, D., Bhardwaj, A., Sahney, A., Maiwall, R., Sarin, S. K., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00049 · Cited by 49
Arrazuria, R., Pérez, V. P., Molina, E., Juste, R. A., Khafipour, E., & Elguezábal, N. (2018) · Scientific Reports · doi:10.1038/s41598-018-32484-1 · Cited by 47
Faivre, S. J., Santoro, A., Kelley, R. K., Merle, P., Gane, E., Douillard, J.-Y., Waldschmidt, D., Mulcahy, M. F., Costentin, C., Minguez, B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.3_suppl.lba173 · Cited by 45
Over-expression of MiR-122 promotes apoptosis of hepatocellular carcinoma via targeting TLR4
Wei, X., Liu, H., Li, X., & Liu, X. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2019.07.005 · Cited by 44
Neoantigens in precision cancer immunotherapy: from identification to clinical applications
Zhang, Q., Jia, Q., Zhang, J., & Zhu, B. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002181 · Cited by 44
Hepatotoxicity and metabolism of trabectedin: a literature review
Beumer, J. H., Schellens, J. H. M., & Beijnen, J. H. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2004.12.001 · Cited by 42
Li, B., Zhang, S., Huang, N., Chen, H., Wang, P., Yang, J. J., & Li, Z. (2018) · Oncology Reports · doi:10.3892/or.2018.6809 · Cited by 41
Manukian, G., Kivolowitz, C., DeAngelis, T., Shastri, A. A., Savage, J. E., Camphausen, K. A., Rodeck, U., Zarif, J. C., & Simone, N. L. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.02.029 · Cited by 41
Yuan, C., Sun, X., Zhu, C., Liu, S., Wu, L., Chen, H., Feng, M., Wu, K., & Wang, X. (2015) · Oncotarget · doi:10.18632/oncotarget.5171 · Cited by 40
TLR 4 increases the stemness and is highly expressed in relapsed human hepatocellular carcinoma
Zhou, S. Y., Du, R., Wang, Z., Shen, W., Gao, R., Jiang, S., Fang, Y., Shi, Y., Chang, A., Liu, L., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2070 · Cited by 40
Self-citationInhibition of allogeneic T-cell response by Kupffer cells expressing indoleamine 2,3-dioxygenase
Yan, M.-L. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i5.636 · Cited by 39
Expression of toll-like receptors in hepatic cirrhosis and hepatocellular carcinoma
Sun, L., Dai, J. J., Hu, W. F., & Wang, J. (2016) · Genetics and Molecular Research · doi:10.4238/gmr.15027419 · Cited by 39
Immune Control in Hepatocellular Carcinoma Development and Progression: Role of Stromal Cells
Sprinzl, M. F., & Galle, P. R. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1394138 · Cited by 38
Wang, Q., Yu, T., Yuan, Y., Zhuang, H., Wang, Z., Liu, X.-S., & Feng, M. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23227 · Cited by 33
Self-citationRong, Y., Wan, Z., Song, H., Li, Y. ‐., Zhu, B., Zang, H., Zhao, Y., Liu, H. ‐., Zhang, A. ‐., Xiao, L., et al. (2014) · Tissue Antigens · doi:10.1111/tan.12278 · Cited by 33
Ecto‐5′‐nucleotidase (CD73) is a potential target of hepatocellular carcinoma
Shali, S., Yu, J., Zhang, X., Wang, X., Jin, Y., Su, M., Liao, X., Yu, J., Zhi, X., & Zhou, P. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27694 · Cited by 28
Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers
Lindblad, K. E., de Galarreta, M. R., & Lujambio, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.642958 · Cited by 28
Wang, T.-T., Yuan, J., Ma, J., Yang, W., Liu, X., Yin, Y., Liu, Y., Pan, W., & Sun, S. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.004 · Cited by 25
Wei, R., Hu, Y., Dong, F., Xu, X., Hu, A., & Gao, G. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2015.110 · Cited by 24
Zhu, L., Li, N., Li, F., Zhou, Z.-H., Sang, J., Jin, Z. Y., Liu, H., Han, Q., Lv, Y., & Liu, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.8435 · Cited by 19
Correlation, consequence, and functionality in microbiome‐immune interplay
Pabst, O. (2017) · Immunological Reviews · doi:10.1111/imr.12584 · Cited by 19
Thanabalasuriar, A., Koutsouris, A., Hecht, G. A., & Gruenheid, S. (2010) · Gut Microbes · doi:10.4161/gmic.1.2.11685 · Cited by 15
Li, H., Li, H., Li, X., Zou, H., Liu, L., Liu, W., & Duan, T. (2018) · Oncology Reports · doi:10.3892/or.2018.6660 · Cited by 15
Shi, Y., Song, Q., Hu, D., Zhuang, X., & Yu, S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.03.177 · Cited by 13
Cited by
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Metadata
- Authors
- Chen, C., Wang, Z., Ding, Y., & Qin, Y.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2023-02-10
- Volume
- 14
- Pages
- 1133308-1133308
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4319984455
- Cited by
- 305
- References
- 295
- FWCI
- 31.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.